ECMO Increased Survival in Refractory Out-of-Hospital Cardiac Arrest
This hyperinvasive approach performed better than expected outcomes also seen in patients who received standard advanced cardiac life support
ECMO unit in use to support a severely ill patient at the University of Michigan. ECMO was shown to imporve survival and neuro outcomes in sudden cardiac arrest patients who do not respond to standard therapy.
May 19, 2021 A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to standard advanced cardiac life support (ACLS), were immediately transported to a cardiac care center and placed on extracorporeal membrane oxygenation (ECMO) were more likely to have survived with good brain function six months later. The outcomes in these patients were better than similar patients who received standard care.
A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to standard advanced cardiac life support (ACLS), were immediately transported to a cardiac care center, and placed on a device similar to a heart-lung bypass machine were more likely to have survived with good brain function six months later than similar patients who received standard care at the site where the OHCA occurred.
Post-Brexit Czechia: Rules and Obligations for British Expats and Visitors praguemorning.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from praguemorning.cz Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') announces today that the Ministry of Health of the Czech Republic
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
February 16, 2021 01:05 ET | Source: Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited North Melbourne, AUSTRALIA
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorisation allowing the use of TLX591-CDx (Kit for the preparation of
68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET).